Office of the Clinical Director

在2021/2022年，临床主任办公室（OCD），校内研究计划（IRP），国家药物滥用研究所（NIDA），美国国立卫生研究院为(6)个独立实验室/临床调查员，（4个终身跟踪/单位负责人和2个高级调查员/分支负责人）和最近的核心/设施负责人提供临床研究支持。2022年1月，临床主任和副主任离职，任命代理临床主任和代理副主任。目前正在进行包括人员和工作流程在内的业务变革，包括将药房转移到行政管理处。NIDA IRP目前的临床研究组合包括各种各样的合作研究，重点是：

In 2021/2022, the Office of the Clinical Director (OCD), Intramural Research Program (IRP), National Institute on Drug Abuse (NIDA), NIH provides clinical research support to (6) independent Laboratories/Clinical investigators, (4 Tenure Track/Unit Chiefs and 2 Senior Investigators/Branch Chiefs) and a recently formerly Core/Facility Head. In January 2022, both the Clinical Director and the Deputy Clinical Director stepped down and an Acting Clinical Director and Acting Deputy Clinical Director were appointed. Operational changes including personnel and workflow are currently underway including the transfer of the Pharmacy to the Administrative Management Branch. The current Clinical research portfolio at the NIDA IRP includes a wide variety of collaborative investigation that focus on: Safety and efficacy of new treatments for addiction. Factors that impact drug taking and relapse. Application of MRI-based structural and functional imaging to elucidate acute and chronic drug effects and their consequences on cognitive processes. Molecular genetic bases of individual differences in vulnerability to develop dependence on an addictive substance. Development of advanced functional and structural magnetic resonance imaging/spectroscopy techniques. Structural MRI techniques to assess tissue integrity related to brain dysfunction. Transcranial magnetic Stimulation (TMS) in the elucidation and treatment of addictive disorders. Mobile health applications for real-time in-the-field addiction treatment interventions.